Brokers Set Expectations for ARTV FY2030 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at HC Wainwright issued their FY2030 earnings per share estimates for Artiva Biotherapeutics in a report issued on Monday, January 26th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.41) per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04.

A number of other analysts have also commented on ARTV. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th. Finally, Wedbush boosted their price target on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Artiva Biotherapeutics Price Performance

ARTV opened at $4.85 on Tuesday. The firm has a 50 day simple moving average of $4.14 and a 200 day simple moving average of $3.51. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.36. The company has a market cap of $119.07 million, a price-to-earnings ratio of -1.88 and a beta of 2.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARTV. Y Intercept Hong Kong Ltd purchased a new position in shares of Artiva Biotherapeutics in the second quarter worth $48,000. Ground Swell Capital LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter worth $38,000. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $41,000. Citadel Advisors LLC lifted its position in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares during the period. Finally, Bank of America Corp DE grew its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.